Article Data

  • Views 626
  • Dowloads 114

Original Research

Open Access

Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy

  • A. Nishikawa1
  • H. Hashimoto2,*,
  • M. Takeda1
  • K. Kontani1
  • T. Miyatake1
  • M. Mimura1
  • M. Nagamatsu1
  • T. Yokoi1

1Kaizuka City Hospital, Kaizuka city, Osaka, Japan

2Sakai City Medical Support Center for Severely Handicapped Children & Persons, Sakai city, Osaka, Japan

DOI: 10.12892/ejgo2843.2016 Vol.37,Issue 4,August 2016 pp.451-454

Published: 10 August 2016

*Corresponding Author(s): H. Hashimoto E-mail: jolly@pc4.so-net.ne.jp

Abstract

Aim: The outcomes of treatment for women with recurrent or advanced epithelial ovarian carcinoma previously treated with paclitaxel plus platinum-based chemotherapy were analyzed. Materials and Methods: Retrospective analysis was performed in a total of 65 series of treatments provided for 35 patients with a history of paclitaxel plus platinum-based chemotherapy. The chemotherapy regimens used were classified into the following four types for analysis: conventional paclitaxel plus carboplatin therapy (TC arm), pegylated liposomal doxorubicin-containing regimens (PLD arm), CPT-11-containing regimens (CPT-11 arm), and others. Disease-control rates (DCRs) were compared and subjected to univariate analysis. Progression-free survival (PFS) was determined from the date of the first cycle of each chemotherapy with the Kaplan-Meier method, and comparisons were performed using the log-rank test. Results: DCR was 80%, 71%, and 26% for the TC, PLD, and CPT-11 arms, respectively. The median PFS was 286, 372, and 76 days for the TC, PLD, and CPT-11 arms, respectively. There was no discernible difference in PFS between the TC and the PLD arm. In contrast, PFS of the CPT- 11 arm was significantly shorter than that of the TC and PLD arms. In addition, three of seven (42.9%) treatments in the PLD arm maintained a progression-free period for longer than one year, while only one of 25 (4%) treatments in the TC arm maintained a progression- free period for more than one year. Conclusions: The PFS of PLD is similar to that of TC. PLD-containing regimens might have a potential benefit with a higher PFS over one year than the TC regimen.

Keywords

CPT-11; Disease control rates; Ovarian carcinoma; Pegylated liposomal doxorubicin; Progression-free survival.

Cite and Share

A. Nishikawa,H. Hashimoto,M. Takeda,K. Kontani,T. Miyatake,M. Mimura,M. Nagamatsu,T. Yokoi. Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy. European Journal of Gynaecological Oncology. 2016. 37(4);451-454.

References

[1] Takayama T., Kato H., Tachimori Y., Watanabe H., Furukawa H., Takayasu K., et al.: “Treatment of rupture of a liver metastasis from esophageal leiomyosarcoma”. Jpn. J. Clin. Oncol., 1996, 26, 248.

[2] Heintz A.P., Odicino F., Maisonneuve P., Quinn M.A., Benedet J.L., Creasman W.T., et al.: “Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer”. Int. J. Gynaecol. Obstet., 2006, 95, S161.

[3] Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al.: “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada”. J. Natl. Cancer Inst., 2000, 92, 205.

[4] Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al.: “Paclitaxel plus platinum─based chemotherapy versus conventional platinum─based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO─OVAR─2.2 trial”. Lancet, 2003, 361, 2099.

[5] González-Martín A.J., Calvo E., Bover I., Rubio M.J., Arcusa A., Casado A., et al.: “Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum─sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study”. Ann. Oncol., 2005, 16, 749.

[6] Pujade-Lauraine E., Wagner U., Aavall-Lundqvist E., Gebski V., Heywood M., Vasey P.A., et al.: “Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carbopratin for patients with platinum─sensitive ovarian cancer in late relapse”. J. Clin. Oncol. 2010, 28, 3323.

[7] Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J.: “Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan”. J. Clin. Oncol., 2001, 19, 3312.

[8] Sugiyama T., Yakushiji M., Nishida T., Ushijima K., Okura N., Kigawa J., et al.: “Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer”. Cancer Lett., 1998, 128, 211.

[9] D'Agostino G., Amant F., Berteloot P., Scambia G., Vergote I.: “Phase II study of gemcitabine in recurrent platinum- and paclitaxelresistant ovarian cancer”. Gynecol. Oncol., 2003, 88, 266.

[10] Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., et al.: “Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer”. J. Clin. Oncol., 2008, 26, 890.

[11] Katsumata N., Fujiwara Y., Kamura T., Nakanishi T., Hatae M., Aoki D., et al.: “Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group”. Jpn. J. Clin. Oncol., 2008, 38, 777.

[12] Bafaloukos D., Linardou H., Aravantinos G., Papadimitriou C., Bamias A., Fountzilas G., et al.: “A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study”. BMC Med., 2010, 8, 3.

[13] Mei L., Chen H., Wei D.M., Fang F., Liu G.J., Xie H.Y., et al.: “Maintenance chemotherapy for ovarian cancer”. Cochrane DatabaseSyst Rev, 2013, CD007414.

[14] Collins Y., Lele S. “Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma”. J. Natl. Med. Assoc., 2005, 97, 1414.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top